What is Evotec SE ADR (EVO) stock price today?

Evotec SE ADR (EVO) currently trades at $2.94 per share. The stock has a market capitalization of $1.04B and a P/E ratio of —x.

Is EVO stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Evotec SE ADR has a Smart Value Score of 43/100 (Grade D), resulting in a "Sell" investment rating. The Piotroski F-Score is 4/9 and Altman Z-Score is 0.48.

What is Evotec SE ADR's revenue and earnings?

Evotec SE ADR has trailing twelve-month (TTM) revenue of $788.37M with profit margins of -13.10%. Earnings per share (EPS) is $-0.34.

Is Evotec SE ADR financially healthy?

Evotec SE ADR's Piotroski F-Score is 4/9 (moderate financial health). The Altman Z-Score of 0.48 places it in the distress.

EVO

Evotec SE ADR

NASDAQ: EVO · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$2.94

-1.34% today

Updated 2026-04-29

Market cap

$1.04B

P/E ratio

—

P/S ratio

1.33x

EPS (TTM)

$-0.34

Dividend yield

—

52W range

$2 – $5

Volume

0.1M

Market cap

$1.04B

P/E ratio

—

P/S ratio

1.33x

EPS (TTM)

$-0.34

Dividend yield

—

52W range

$2 – $5

Volume

0.1M

WallStSmart proprietary scores

out of 100

Grade: D

Sell

Investment rating

4.7

Growth

5.3

Quality

C+

3.0

Profitability

5.3

Valuation

C+

4/9

Piotroski F-Score

Moderate

0.5

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →201 stocks currently score above 75

Price targets

Analyst target

$5.21

+77.21%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy2 Buy0 Hold0 Sell1 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Free cash flow $46.56M — positive

+ Revenue growth 14.50% QoQ

Risks

- Altman Z 0.48 — distress zone

- Thin margins at -13.10%

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$751.45M	$781.43M	$796.97M	$757.26M	$788.37M
Net income	$-175.66M	$-83.91M	$-196.08M	$-99.43M	$14.49M
EPS	—	—	—	—	$-0.34
Free cash flow	$24.46M	$-182.05M	$-114.02M	$-78.74M	$46.56M
Profit margin	-23.38%	-10.74%	-24.60%	-13.13%	-13.10%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
EVO	$1.04B	43	4.7	3.0	5.3	5.3	—	Hold
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Evotec SE ADR trades at $2.94. Our Smart Value Score of 43/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 0.48, it sits in the distress. TTM revenue stands at $788.37M. with profit margins at -13.10%.

Frequently asked questions

What is Evotec SE ADR's stock price?

Evotec SE ADR (EVO) trades at $2.94.

Is Evotec SE ADR overvalued?

Smart Value Score 43/100 (Grade D, Sell).

What is the price target of Evotec SE ADR (EVO)?

The analyst target price is $5.21, representing +77.2% upside from the current price of $2.94.

What is Evotec SE ADR's revenue?

TTM revenue is $788.37M.

Piotroski F-Score?

4/9 — moderate financial health.

Altman Z-Score?

0.48 — distress.

Company info

SectorHEALTHCARE

IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio1.33x

ROE-11.70%

Beta1.24

50D MA$2.89

200D MA$3.40

Shares out0.36B

Float0.13B

Short ratio—

Avg volume0.1M

Performance

1 week+22.43%

1 month+31.97%

3 months-10.80%

YTD+4.55%

1 year—

3 years—

5 years—

Compare

EVO vs LLY →EVO vs JNJ →EVO vs ABBV →Stock screener →